Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma: This section shines light on the better management of the toxicities of immune-checkpoint inhibitor in melanoma treatments.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma: The FDA has fast-tracked the approval process for SRN-101, a novel treatment entity for recurrent high-grade glioma, a form of brain cancer.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma: A potential breakthrough in the treatment of multiple myeloma, this section discusses the efficacy of a newly identified molecule.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC: This section investigates life quality outcomes between proton therapy and photon therapy in patients with oropharyngeal squamous cell carcinomas.
3 Things You Should Know About PSMA-Directed Imaging and Radioligand Therapy in Prostate Cancer: Explore critical pointers about PSMA-directed Imaging and Radioligand Therapy in the treatment of prostate cancer.
